Worldwide Emergence of Extensively Drug-resistant Tuberculosis
Top Cited Papers
- 1 March 2007
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 13 (3), 380-387
- https://doi.org/10.3201/eid1303.061400
Abstract
Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates that were resistant to second-line anti-TB drugs during 2000-2004. We defined extensively drug-resistant TB (XDR TB) as MDR TB with further resistance to ≥3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR TB isolates, 347 (9.9%) met criteria for XDR TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR TB are crucial for protection of public health and control of TBKeywords
This publication has 29 references indexed in Scilit:
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaThe Lancet, 2006
- Extensively Drug‐Resistant Tuberculosis: 2 Years of Surveillance in IranClinical Infectious Diseases, 2006
- Multidrug-resistant Tuberculosis Management in Resource-limited SettingsEmerging Infectious Diseases, 2006
- Global Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2006
- Evaluation of MGIT 960-Based Antimicrobial Testing and Determination of Critical Concentrations of First- and Second-Line Antimicrobial Drugs with Drug-Resistant Clinical Strains of Mycobacterium tuberculosisJournal of Clinical Microbiology, 2006
- Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer AntimicrobialsJournal of Clinical Microbiology, 2006
- Increasing transparency in partnerships for health - introducing the Green Light CommitteeTropical Medicine & International Health, 2002
- Treatment of Multidrug-Resistant TuberculosisThe New England Journal of Medicine, 1993
- An Outbreak of Multidrug-Resistant Tuberculosis among Hospitalized Patients with the Acquired Immunodeficiency SyndromeThe New England Journal of Medicine, 1992
- Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycinTubercle, 1977